Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Liang, Xiao Dong ^a   Dai, Yue Chu ^b   Li, Zhao Yun ^b   Gan, Mei Fu ^c   Zhang, Shi Rong ^a   Yin Pan, ^b   Lu, Hong Sheng ^b   Cao, Xue Quan ^b   Zheng, Bei Jia ^b   Bao, Ling Fen ^b   Wang, Dan Dan ^b   Zhang, Li Ming ^b   Ma, Sheng Lin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Central Hospital of Taizhou City   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER TISSUE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HEPG2 CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; MITOTIC SPINDLE CHECKPOINT GENE; MOUSE; NONHUMAN; TTK GENE; UPREGULATION;

EID: 84902591282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097739     Document Type: Article

References (43)

1. Cormier JN, Thomas KT, Chari RS, Pinson CW (2006) Management of hepatocellular carcinoma. J Gastrointest Surg 10: 761-780. (Pubitemid 43711147)
2. Masuzaki R, Omata M (2008) Treatment of hepatocellular carcinoma. Indian J Gastroenterol 27: 113-122.
3. Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, et al. (2013) Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 109: 888-890.
4. Carr BI, D'Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, et al. (2013) Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol 228: 1344-1350.
5. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
8. Musacchio A (2011) Spindle assembly checkpoint: the third decade. Philos Trans R Soc Lond B Biol Sci 366: 3595-3604.
9. Musacchio A, Ciliberto A (2012) The spindle-assembly checkpoint and the beauty of self-destruction. Nat Struct Mol Biol 19: 1059-1061.
10. Li Y, Benezra R (1996) Identification of a human mitotic checkpoint gene: hsMAD2. Science 274: 246-248.
11. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303. (Pubitemid 28155105)
12. Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101: 8699-8704. (Pubitemid 38745834)
13. Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785. (Pubitemid 41400777)
14. Saeki A, Tamura S, Ito N, Kiso S, Matsuda Y, et al. (2002) Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Cancer 94: 2047-2054. (Pubitemid 34270059)
15. Nishida N, Kudo M (2013) Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 84 Suppl 1: 93-97.
16. Nakagawa H, Shibata T (2012) Comprehensive genome sequencing of the liver cancer genome. Cancer Lett.
17. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, et al. (2011) Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 337: 155-161.
18. Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, et al. (2012) Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 40: 1005-1010.
19. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, et al. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506-2513.
20. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574. (Pubitemid 46295136)
21. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, et al. (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18: 244-257.
22. Janssen A, Kops GJ, Medema RH (2011) Targeting the mitotic checkpoint to kill tumor cells. Horm Cancer 2: 113-116.
23. Manchado E, Guillamot M, Malumbres M (2012) Killing cells by targeting mitosis. Cell Death Differ 19: 369-377.
24. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, et al. (2009) Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 69: 2775-2782.
25. Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM, et al. (2007) Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res 67: 130-138. (Pubitemid 46142768)
26. Yeh CT, Lu SC, Chen TC, Peng CY, Liaw YF (2000) Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res 60: 4697-4700.
27. Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, et al. (2002) Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 22: 259-268. (Pubitemid 34846365)
28. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, et al. (2000) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59: 68-74. (Pubitemid 30435839)
29. Wang X, Meng X, Sun X, Liu M, Gao S, et al. (2009) Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle 8: 1567-1570.
30. Liu L, Dong Z, Liang J, Cao C, Sun J, et al. (2013) As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3beta pathway. Oncogene.
31. Kim HE, Kim DG, Lee KJ, Son JG, Song MY, et al. (2012) Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One 7: e43223.
32. Qin X, Yuan B, Xu X, Huang H, Liu Y (2013) Effects of short interfering RNA-mediated gene silencing of SKA1 on proliferation of hepatocellular carcinoma cells. Scand J Gastroenterol.
33. Fisk HA, Mattison CP, Winey M (2004) A field guide to the Mps1 family of protein kinases. Cell Cycle 3: 439-442. (Pubitemid 40278232)
34. Tighe A, Staples O, Taylor S (2008) Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol 181: 893-901. (Pubitemid 351846823)
35. Maciejowski J, George KA, Terret ME, Zhang C, Shokat KM, et al. (2010) Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol 190: 89-100.
36. Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, et al. (2013) Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst 105: 1322-1331.
37. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, et al. (2013) TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One 8: e63712.
38. Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E (2011) High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci U S A 108: 5384-5389.
39. Niittymaki I, Gylfe A, Laine L, Laakso M, Lehtonen HJ, et al. (2011) High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint. Carcinogenesis 32: 305-311.
40. Zhai B, Sun XY (2013) Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 5: 345-352.
41. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, et al. (2010) Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol 17: 603-612.
42. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, et al. (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57: 108-115.
43. Zhang L, Shi R, He C, Cheng C, Song B, et al. (2013) Oncogenic B-Raf (V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. Cancer Lett 337: 125-132.